Elmstedt E, Lindholm T S, Nilsson O S, Törnkvist H
Acta Orthop Scand. 1985 Feb;56(1):25-7. doi: 10.3109/17453678508992973.
A double-blind, placebo-controlled study was made of the influence of the anti-inflammatory agent ibuprofen on heterotopic ossification after total hip replacement for arthrosis, fracture or rheumatoid arthritis. Seven drop-outs left 21 patients on medication and 22 on placebo in two comparable groups. Heterotopic ossification appeared in one third of the patients in the ibuprofen group and in three fourths in the control group 12 months after surgery. Five patients in the latter group developed true heterotopic bone, compared to one of the patients on medication. Heterotopic ossification was as common among osteoarthritic patients as among others. There was no difference in the range of motion at 12 months postoperatively between patients with and without heterotopic ossification. In the 22 patients with heterotopic ossification this was demonstrated in all but eight within 6 weeks, and in only three did it appear later than 3 months postoperatively. Five of the six patients who showed heterotopic bone with trabecular structure were male. Since inflammation is a dominant feature in the postoperative phase, the effect of ibuprofen on heterotopic ossification is probably its inhibition of the synthesis of prostaglandins. This implies that prevention is most successful if commenced before or at the time of operation.
一项双盲、安慰剂对照研究探讨了抗炎药物布洛芬对因骨关节炎、骨折或类风湿性关节炎行全髋关节置换术后异位骨化的影响。7名退出者使两个可比组中分别有21名患者服用药物和22名患者服用安慰剂。术后12个月，布洛芬组三分之一的患者出现异位骨化，而对照组为四分之三。后一组中有5名患者形成了真正的异位骨，而服用药物的患者中只有1名出现这种情况。异位骨化在骨关节炎患者中与其他患者中一样常见。术后12个月，有异位骨化和没有异位骨化的患者在活动范围上没有差异。在22例有异位骨化的患者中，除8例之外，其余患者均在6周内出现，只有3例在术后3个月后出现。显示有小梁结构异位骨的6例患者中有5例为男性。由于炎症是术后阶段的主要特征，布洛芬对异位骨化的作用可能是其对前列腺素合成的抑制。这意味着如果在手术前或手术时开始预防最为成功。
